|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ZNF263 |
Gene summary for ZNF263 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ZNF263 | Gene ID | 10127 |
| Gene name | zinc finger protein 263 | |
| Gene Alias | FPM315 | |
| Cytomap | 16p13.3 | |
| Gene Type | protein-coding | GO ID | GO:0000122 | UniProtAcc | O14978 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10127 | ZNF263 | P57T-E | Human | Esophagus | ESCC | 2.14e-06 | 1.58e-01 | 0.0926 |
| 10127 | ZNF263 | P61T-E | Human | Esophagus | ESCC | 3.94e-09 | 2.75e-01 | 0.099 |
| 10127 | ZNF263 | P62T-E | Human | Esophagus | ESCC | 5.52e-36 | 7.16e-01 | 0.1302 |
| 10127 | ZNF263 | P65T-E | Human | Esophagus | ESCC | 4.44e-09 | 1.13e-01 | 0.0978 |
| 10127 | ZNF263 | P74T-E | Human | Esophagus | ESCC | 4.88e-04 | 4.16e-02 | 0.1479 |
| 10127 | ZNF263 | P75T-E | Human | Esophagus | ESCC | 6.99e-14 | 2.40e-01 | 0.1125 |
| 10127 | ZNF263 | P76T-E | Human | Esophagus | ESCC | 1.14e-07 | 4.79e-02 | 0.1207 |
| 10127 | ZNF263 | P79T-E | Human | Esophagus | ESCC | 5.08e-15 | 1.67e-01 | 0.1154 |
| 10127 | ZNF263 | P80T-E | Human | Esophagus | ESCC | 4.49e-12 | 4.24e-01 | 0.155 |
| 10127 | ZNF263 | P83T-E | Human | Esophagus | ESCC | 3.99e-10 | 2.57e-01 | 0.1738 |
| 10127 | ZNF263 | P107T-E | Human | Esophagus | ESCC | 1.01e-06 | 1.55e-01 | 0.171 |
| 10127 | ZNF263 | P126T-E | Human | Esophagus | ESCC | 4.40e-02 | 3.29e-01 | 0.1125 |
| 10127 | ZNF263 | P127T-E | Human | Esophagus | ESCC | 3.15e-14 | 1.44e-01 | 0.0826 |
| 10127 | ZNF263 | P128T-E | Human | Esophagus | ESCC | 1.05e-11 | 3.92e-01 | 0.1241 |
| 10127 | ZNF263 | P130T-E | Human | Esophagus | ESCC | 7.11e-11 | 2.65e-01 | 0.1676 |
| 10127 | ZNF263 | HCC1_Meng | Human | Liver | HCC | 2.92e-08 | -4.98e-02 | 0.0246 |
| 10127 | ZNF263 | HCC2_Meng | Human | Liver | HCC | 1.23e-04 | -8.81e-03 | 0.0107 |
| 10127 | ZNF263 | HCC2 | Human | Liver | HCC | 9.03e-03 | 3.37e+00 | 0.5341 |
| 10127 | ZNF263 | S014 | Human | Liver | HCC | 2.73e-04 | 3.07e-01 | 0.2254 |
| 10127 | ZNF263 | S015 | Human | Liver | HCC | 4.37e-03 | 3.31e-01 | 0.2375 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ZNF263 | TUF | Colorectum | FAP | NEK10,AC087386.1,C17orf67, etc. | 3.24e-02 |  |
| ZNF263 | CT | Colorectum | FAP | NEK10,AC087386.1,C17orf67, etc. | 1.68e-03 | |
| ZNF263 | EE | Colorectum | FAP | NEK10,AC087386.1,C17orf67, etc. | 1.28e-03 | |
| ZNF263 | SSC | Colorectum | FAP | NEK10,AC087386.1,C17orf67, etc. | 0.00e+00 | |
| ZNF263 | DC | Colorectum | CRC | OSBPL3,ABCA5,PTEN, etc. | 7.50e-02 |  |
| ZNF263 | DC | Colorectum | FAP | OSBPL3,ABCA5,PTEN, etc. | 9.78e-02 | |
| ZNF263 | CHO | Liver | NAFLD | RABGAP1,NR2F2-AS1,MSI2, etc. | 3.93e-01 |  |
| ZNF263 | CILIA | Lung | Healthy | SFT2D1,ETFB,SMURF1, etc. | 1.99e-02 |  |
| ZNF263 | NUER | Prostate | Tumor | TSPAN12,GPR37,KMT2E-AS1, etc. | 2.36e-03 |  |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ZNF263 | SNV | Missense_Mutation | novel | c.404G>T | p.Arg135Leu | p.R135L | O14978 | protein_coding | deleterious(0.02) | benign(0.062) | TCGA-A7-A0DB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
| ZNF263 | SNV | Missense_Mutation | c.716N>C | p.Arg239Thr | p.R239T | O14978 | protein_coding | deleterious(0.01) | benign(0.133) | TCGA-A8-A08L-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
| ZNF263 | SNV | Missense_Mutation | novel | c.1193G>T | p.Arg398Ile | p.R398I | O14978 | protein_coding | tolerated(0.14) | possibly_damaging(0.82) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ZNF263 | SNV | Missense_Mutation | novel | c.1207N>A | p.Glu403Lys | p.E403K | O14978 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-BH-A2L8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | CR |
| ZNF263 | SNV | Missense_Mutation | rs750738145 | c.1012N>T | p.His338Tyr | p.H338Y | O14978 | protein_coding | deleterious(0.04) | benign(0.011) | TCGA-D8-A1XW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin+cyclophosphamide | SD |
| ZNF263 | insertion | Nonsense_Mutation | novel | c.429_430insACCTGACGATGGCGTCGGGC | p.Pro144ThrfsTer2 | p.P144Tfs*2 | O14978 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| ZNF263 | insertion | Frame_Shift_Ins | novel | c.1038_1039insA | p.Pro347ThrfsTer43 | p.P347Tfs*43 | O14978 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| ZNF263 | insertion | In_Frame_Ins | novel | c.1039_1040insAGAGTGAGACTCTGT | p.Pro347delinsGlnSerGluThrLeuSer | p.P347delinsQSETLS | O14978 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| ZNF263 | deletion | Frame_Shift_Del | novel | c.544delG | p.Asp182ThrfsTer5 | p.D182Tfs*5 | O14978 | protein_coding | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD | ||
| ZNF263 | SNV | Missense_Mutation | novel | c.1907N>A | p.Cys636Tyr | p.C636Y | O14978 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |